Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Wider access to GLP-1 medicines (glucagon-like peptide-1) for obesity and diabetes will help reduce the burden of these conditions.''Winselow Tucker, president and GM, Eli Lilly and Co (India) said: "India is entering a transformative phase in obesity and chronic weight-management care, driven by a rising disease burden, greater recognition of obesity as a chronic disease, and broader access to evidence-based prescription therapies
Proper injection techniques and sterile conditions help reduce these risks
This design leaves the peptides sequence and structure virtually unchanged aside from one atom, thus minimizing disruption of GLP-1R binding and likely reducing immunogenic risk 17,18
In Phase 2 trials, retatrutide was administered as a once-weekly subcutaneous injection using a gradual dose escalation schedule to minimise gastrointestinal side effects
